WAKIX Drug Patent Profile

When do Wakix patents expire, and what generic alternatives are available?

Wakix is a drug marketed by Harmony and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-one patent family members in thirty-one countries.

The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this compound. Additional details are available on the pitolisant hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Wakix

Wakix was eligible for patent challenges on August 14, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 21, 2031. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for WAKIX

International Patents:	61
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	64
Patent Applications:	337
Drug Prices:	Drug price information for WAKIX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for WAKIX
What excipients (inactive ingredients) are in WAKIX?	WAKIX excipients list
DailyMed Link:	WAKIX at DailyMed

See drug prices for WAKIX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for WAKIX

Constraining patent/regulatory exclusivity:

TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH NARCOLEPSY

NDA:

211150

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for WAKIX

Drug Class	Histamine-3 Receptor Antagonist/Inverse Agonist
Mechanism of Action	Cytochrome P450 3A4 Inducers Histamine H3 Receptor Antagonists Histamine H3 Receptor Inverse Agonists

Paragraph IV (Patent) Challenges for WAKIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WAKIX	Tablets	pitolisant hydrochloride	4.45 mg and 17.8 mg	211150	7	2023-08-14

US Patents and Regulatory Information for WAKIX

WAKIX is protected by five US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH NARCOLEPSY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019		RX	Yes	No
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019		RX	Yes	Yes
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019		RX	Yes	No

Expired US Patents for WAKIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019

International Patents for WAKIX

See the table below for patents covering WAKIX around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2014062126	TREATMENT OF SYMPTOMS OF PARKINSON'S DISEASE, OBSTRUCTIVE SLEEP APNEA, DEMENTIA WITH LEWY BODIES, VASCULAR DEMENTIA WITH NON-IMIDAZOLE ALKYLAMINE HISTAMINE H3-RECEPTOR LIGANDS
Taiwan	I393711
Morocco	29353	TRAITEMENT DE LA MALADIE DE PARKINSON, DE L'APNEE OBSTRUCTIVE DU SOMMEIL, DE LA DEMENCE A CORPS DE LEWY, DE LA DEMENCE VASCULAIRE, AVEC DES LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE NON-IMIDAZOLE-ALKYLAMINES

Supplementary Protection Certificates for WAKIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1428820	16C0038	France		PRODUCT NAME: PITOLISANT ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/15/1068 20160331
1428820	300832	Netherlands		PRODUCT NAME: PITOLISANT EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN, ZOALS HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/15/1068/002 20160404
1428820	SPC/GB16/052	United Kingdom		PRODUCT NAME: PITOLISANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, SUCH AS HYDROCHLORIDE; REGISTERED: UK EU/1/15/1068 20160404

Market Dynamics and Financial Trajectory for WAKIX

Last updated: February 19, 2026

What is WAKIX and its approved indications?

WAKIX (pitolisant) is a prescription medication developed by Harmony Biosciences. It received FDA approval in August 2019 for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy in adult patients. It is also approved in Europe under the name Wakix for similar indications.

WAKIX functions as a histamine 3 (H3) receptor antagonist/inverse agonist, promoting wakefulness. Its mechanism is distinct from other narcolepsy treatments such as modafinil or sodium oxybate.

What are the key market drivers influencing WAKIX's growth?

Market size of narcolepsy and EDS markets

The global narcolepsy market was valued at approximately $300 million in 2022. It is projected to grow at a CAGR of 8% through 2030, driven by increased awareness and diagnosis rates.

• Estimated diagnosed narcolepsy patients in the U.S.: 135,000.
• Estimated global prevalence: 1 in 2,000 individuals.
• EDS associated with narcolepsy represents a subset but also coexists with other disorders such as idiopathic hypersomnia.

Competition and differentiators

WAKIX's primary competitors include:

• Modafinil (Provigil) and armodafinil (Nuvigil): Stimulants with broad use in narcolepsy and shift work sleep disorder.
• Sodium oxybate (Xyrem): Approved for narcolepsy with cataplexy, effective but with strict storage and administration requirements.
• Solriamfetol (Sunosi): Approved for narcolepsy and OSA-related EDS, marketed by Jazz Pharmaceuticals.

WAKIX's advantages are:

• No Schedule IV drug classification.
• Favorable side-effect profile relative to stimulants.
• Daily oral dosing with no need for approval restrictions that sodium oxybate has.

Regulatory and reimbursement factors

WAKIX's approval in multiple regions has expanded its accessibility. Insurance coverage, especially in the U.S., depends on formulary placement, with initial challenges due to its relative novelty. Pricing was introduced at approximately $350 per month in the U.S. in 2019 and remains a key factor affecting penetration.

What are the financials and sales trajectory since launch?

Sales performance overview

• 2020: $27 million in U.S. net sales.
• 2021: $102 million, a 278% increase.
• 2022: $243 million, a 138% rise from 2021.

The sales growth reflects increased prescriber familiarity and expanded market access. The company targets sales of over $400 million in 2023.

Revenue projections

Based on current market penetration, sales are expected to reach approximately $500 million by 2024, assuming continued adoption and favorable reimbursement.

Revenue contribution and margins

• WAKIX's gross margins are approximately 85%.
• Operating margins depend on marketing expenses and R&D investments for pipeline expansion.

How are potential future developments shaping the market?

Pipeline and label expansion

• WAKIX's developers are pursuing approval for treatment of idiopathic hypersomnia.
• Studies are ongoing for WAKIX in other sleep-wake disorders, which could expand its market.

Strategic partnerships and market expansion

• Efforts to expand into European markets complement recent approvals.
• Collaborations with payers to improve formulary acceptance aim to bolster sales.

What are the key risks impacting WAKIX's financial trajectory?

• Competitive erosion from newer agents like solriamfetol and other emerging therapies.
• Pricing pressure and reimbursement restrictions.
• Slower-than-expected diagnosis and delays in market penetration.

Summarizing market outlook

The narcolepsy and EDS treatments market faces steady growth driven by increased awareness and expanded indications. WAKIX benefits from unique mechanism, favorable side effect profile, and recent approvals. Its sales trajectory hinges on market access and competition dynamics.

Key Takeaways

• WAKIX's U.S. sales grew from $27 million in 2020 to $243 million in 2022.
• The global narcolepsy market is projected to reach over $700 million by 2030.
• Competitive landscape includes stimulants, sodium oxybate, and newer agents like solriamfetol.
• Future growth depends on widening indications and improving payer access.
• Long-term success is subject to market penetration, competition, and regulatory developments.

FAQs

Q1: How does WAKIX differ from stimulant therapies for narcolepsy?
WAKIX targets histamine pathways, lacks stimulant side effects, and has no Schedule IV designation, unlike modafinil or armodafinil.

Q2: What are the primary barriers to WAKIX's market growth?
Pricing, reimbursement hurdles, limited awareness among physicians, and competition from established stimulants.

Q3: Is WAKIX approved outside the U.S.?
Yes, it has approval in Europe under the brand Wakix, with ongoing efforts for other markets.

Q4: What is the outlook for WAKIX's pipeline expansion?
Progress in indications for idiopathic hypersomnia and additional sleep disorders supports potential label expansion.

Q5: How has WAKIX's market share changed over time?
It has increased significantly since launch, capturing a segment of the narcolepsy treatment market, though still below stimulants' market share.

---

References

[1] MarketWatch. (2023). Global narcolepsy market size, share & trends analysis. Retrieved from https://www.marketwatch.com

[2] Harmony Biosciences. (2022). Annual report.

[3] IQVIA. (2023). Prescription drug market analysis.

[4] U.S. Food and Drug Administration. (2019). WAKIX approval letter.

[5] Grand View Research. (2022). Sleep disorder therapeutics market size, share & trends.